Clinical Trial Update: Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating orteronel with itraconazole in men with castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Itraconazole (Itraconazole)
• Orteronel (Orteronel)

Snippet

Sponsor: Emmanuel Antonarakis, MD | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN